Adbry (tralokinumab-ldrm) News

«1 234 5 6 7 8 9 10 11 12 13 »

|||||||||| Clinical, Journal: Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice. (Pubmed Central) - Mar 9, 2024
Consequently, there is an unmet need to determine an algorithmic step-by-step approach of treat-to-target and switching or adding treatment in the current landscape of AD therapy. Different policies of reimbursement in different countries, along with a lack of comparative studies, may complicate adding such recommendations to existing treatment guidelines.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
IND7 - Insights into Adbry (Exhibit Hall - Theater 1) - Mar 1, 2024 - Abstract #AAD2024AAD_3719;
Different policies of reimbursement in different countries, along with a lack of comparative studies, may complicate adding such recommendations to existing treatment guidelines. Description A patient-focused program where two leading dermatologists review the latest efficacy and safety data of Adbry

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series. (Pubmed Central) - Feb 29, 2024
Description A patient-focused program where two leading dermatologists review the latest efficacy and safety data of Adbry No abstract available

|||||||||| Review, Journal: Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma. (Pubmed Central) - Feb 24, 2024
This review analyzes current knowledge on the IL-4/IL-13 axis in mycosis fungoides and Sezary syndrome, the most common types of CTCL, examining existing literature on the pathogenetic implications with a focus on investigational treatments. Clinical trials and case reports are required to shed light on novel uses of medications in various diseases, and ongoing research into the role of IL-4/IL-13 axis blockers in CTCL therapy might not only improve the management of disease-related pruritus but also provide in-depth insights on the pathophysiologic mechanisms of CTCL.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Comparison of different skincare regimens for patients with moderate-to-severe atopic dermatitis in addition to systemic treatment: results of a multicenter randomized controlled trial () - Feb 20, 2024 - Abstract #AAD2024AAD_2729;
Introduction: Moderate-to-severe (MTS) atopic dermatitis (AD) can be managed by systemic treatment with drugs such as Cyclosporin A, biologics (Dupilumab, Tralokinumab) or small molecules such as JAK inhibitors. In patients with MTS AD treated with Dupilumab, adjunctive skin care with Emollient+ significantly improves pruritus symptoms and quality-of-life aspects compared to routine skin care.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
A Single-Center Retrospective Case Series of Treatment Response to Tralokinumab in Patients with Moderate to Severe Atopic Dermatitis (AD) (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_2709;
Our study indicates that tralokinumab is effective in treatment of moderate-to-severe AD, even among patients who experienced side effects, secondary loss of efficacy, or primary lack of response on dupilumab. Of 22 such patients who failed dupilumab therapy, 17 (77.3%) responded favorably to tralokinumab.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis () - Feb 20, 2024 - Abstract #AAD2024AAD_2701;
P3
A stable EASI ?2 response was observed in 34.0% (113/332) of patients, and a long-term optimal composite target, EASI ?7 and either DLQI ?5 or Itch NRS ?4, was observed in 60.5% (201/332) of patients. High proportions of clinical trial patients maintained stable responses, with no or minimal fluctuations in efficacy, with continued tralokinumab 300 mg Q2W plus optional TCS for up to 4 years of treatment.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Efficacy of Tralokinumab in Patients with Moderate to Severe Atopic Dermatitis Who Failed Treatment with Dupilumab (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_2678;
27 patients were able to start tralokinumab. After an average of 6 months, 59% of patients experienced partial (9/27) to complete resolution (7/27) of their AD symptoms.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
A Prospective Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_2664;
At month six, this increased to 7/8 EASI75; 6/8 IGA 0/1; 7/8 PP-NRS4; 8/8 DLQI4. Tralokinumab treatment resulted in marked skin clearance, itch and quality-of-life improvement, and no adverse events, suggesting potential context-dependent mechanistic, differences conferred by targeting of IL-13 vs. IL-4R?.

|||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Rinvoq (upadacitinib) / AbbVie
Real-world experience of switching atopic dermatitis treatment to upadacitinib after primary or secondary dupilumab failure (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_2655;
Dupilumab was the first biological agent approved for atopic dermatitis (AD), maintaining its status as the solitary targeted treatment for years until the recent approvals of tralokinumab and janus kinase (JAK) inhibitors. AD patients who have previously failed dupilumab treatment may be considered

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
e-Lung CT Biomarkers Can Stratify Patients at Risk of IPF Progression at 52 Weeks; Post-hoc Analysis From a Randomised Control Trial (San Diego Convention Center, Room 33A-C (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5429;
P2
In the Phase 2 IPF tralokinumab clinical trial (NCT01629667), which was discontinued on efficacy grounds, patients had baseline but no follow-up CT scans...These data suggest that the e-Lung WRVS tool may allow enrichment of clinical trials for progressive patients, identify patients at low risk of IPF progression, and facilitate well-matched treatment arms. Further work is ongoing to validate these findings in additional cohorts.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata. (Pubmed Central) - Feb 19, 2024
Further work is ongoing to validate these findings in additional cohorts. No abstract available

|||||||||| Journal: S3 guideline Atopic dermatitis: Part 2 - Systemic treatment. (Pubmed Central) - Feb 19, 2024
Additionally, it discusses systemic off-label therapies. The first part of the guideline, published separately, includes the definition and diagnostic aspects of AD, describes topical therapy, non-drug therapy approaches, and addresses aspects related to special patient groups.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Rinvoq (upadacitinib) / AbbVie, Cibinqo (abrocitinib) / Pfizer
Review: Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. (Pubmed Central) - Feb 12, 2024
4. See the NIHR Funding and Awards website for further award information.

|||||||||| Retrospective data, Review, Journal: Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis. (Pubmed Central) - Jan 27, 2024
Baricitinib_4?mg and ritlecitinib 200_50?mg demonstrated notable efficacy, and both molecules displayed a dose-dependent effect, which is not observed with ivarmacitinib. Further investigations into the specific mechanisms of action of these JAK inhibitors are warranted to elucidate the reasons behind these differences.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. (Pubmed Central) - Jan 23, 2024
ISR was a frequent occurrence in both the treatment groups, with tralokinumab causing ISR more frequently than dupilumab. However, the reactions were generally mild and no patient stopped therapy.

|||||||||| Cibinqo (abrocitinib) / Pfizer
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain. (Pubmed Central) - Jan 18, 2024
However, the reactions were generally mild and no patient stopped therapy. The results of the study show that abrocitinib is a cost-effective therapy compared with other JAK inhibitors and biological therapies from the Spanish NHS perspective.

|||||||||| Journal: Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. (Pubmed Central) - Jan 15, 2024
The results of the study show that abrocitinib is a cost-effective therapy compared with other JAK inhibitors and biological therapies from the Spanish NHS perspective. The evidence supported strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib and conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids.

|||||||||| Journal: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. (Pubmed Central) - Jan 15, 2024
We make strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib. We make conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Review, Journal: Considerations for managing elderly patients with atopic dermatitis. (Pubmed Central) - Jan 9, 2024
Indeed, systemic therapies for AD are often contraindicated or not tolerated and the management of elderly type AD is often burdened with numerous difficulties, leading to undertreated disease. Even if dupilumab and tralokinumab represent a valuable therapeutic weapon, more data on safety of JAK inhibitors are required.

|||||||||| Review, Journal, Metastases: Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. (Pubmed Central) - Jan 8, 2024
in 2017), tralokinumab (anti-IL-13 in 2021), lebrikizumab (anti-IL-13 in 2023), and the oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib in 2020 in the EU) or JAK1 (upadacitinib in 2021 and abrocitinib in 2022)...Among the topical therapies, tapinarof (aryl hydrocarbon receptor), ruxolitinib (JAK1/2i), delgocitinib (pan-JAKi), asivatrep (anti-transient receptor potential vanilloid), and phosphodiesterase-4-inhibitors (roflumilast, difamilast) are discussed. Among systemic therapies, current data on cord-blood-derived mesenchymal stem cells, CM310 (anti IL-4R?), nemolizumab (anti-IL-31RA), anti-OX40/OX40L-antibodies, neurokinin-receptor-1-antagonists, and difelikefalin (?-opioid-R) are reported.

|||||||||| U029 - Practical Considerations for Systemic Treatment of Atopic Dermatitis in Adults (Room 31B) - Jan 5, 2024 - Abstract #AAD2024AAD_357;
Recognize adverse events associated with systemic treatments for atopic dermatitis and how to monitor for and manage them. Differentiate the advantages and disadvantages of available systemic treatment options for atopic dermatitis in special populations of adults, including older adults and adults with comorbidities.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Clinical, Retrospective data, Journal: Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study. (Pubmed Central) - Dec 18, 2023
Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16. This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32?weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.

|||||||||| Retrospective data, Review, Journal: Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. (Pubmed Central) - Dec 17, 2023
High-dose abrocitinib and low-dose upadacitinib are effective, but also among the most harmful. Dupilumab, lebrikizumab, and tralokinumab are of intermediate effectiveness and have favorable safety.

|||||||||| Review, Journal: An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults. (Pubmed Central) - Dec 6, 2023
Some monoclonal antibodies, such as dupilumab (anti-IL-4?R?) and tralokinumab (anti-IL13) are already approved for the treatment of moderate-to-severe atopic dermatitis, and numerous articles in the literature have demonstrated their efficacy and safety...Data from phase 2b and phase III clinical trials in moderate-to-severe atopic dermatitis in adults indicate that these drugs have a promising efficacy and safety profile. Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Tralokinumab treatment in atopic dermatitis: Depicting super-responders. (Pubmed Central) - Dec 4, 2023
Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety. No abstract available

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Effectiveness Of Treatment Of Tralokinumab In Treatment Of Atopic Dermatitis In Adolescents. (Pubmed Central) - Dec 2, 2023
No abstract available No abstract available

|||||||||| Journal, Adverse events, Real-world evidence, Real-world, Immunomodulating: Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. (Pubmed Central) - Nov 30, 2023
Real-world reported AEs captured in AD patient registries can add information on the estimated incidence of AEs and benefit clinical decision aids. Future studies using data derived from the TREAT NL registry combined with data from other registries within the TREAT Registry Taskforce will provide more information on (rare) AEs associated with immunomodulating therapy in AD patients.

|||||||||| Review, Journal, Combination therapy: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids. (Pubmed Central) - Nov 28, 2023
Long-term safety considerations and differences in the time-effect and safety profiles of various medications are also noted to help inform clinical decisions for individual patients. Overall, the findings of these trials support efficacy in long-term treatment with novel systemic agents for patients with AD.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
P3 data, Journal: Tralokinumab Efficacy Over 1 (Pubmed Central) - Nov 28, 2023
P3
Overall, the findings of these trials support efficacy in long-term treatment with novel systemic agents for patients with AD. Tralokinumab treatment provides progressive and sustained improvement over 1 year in the extent and severity of AD in patients with moderate-to-severe AD.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal, Patient reported outcomes: Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience. (Pubmed Central) - Nov 27, 2023
Tralokinumab treatment provides progressive and sustained improvement over 1 year in the extent and severity of AD in patients with moderate-to-severe AD. No abstract available

||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Phase classification, Monotherapy:  ADHAND: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (clinicaltrials.gov) -  Nov 20, 2023
P3, N=402, Recruiting,  Sponsor: LEO Pharma
No abstract available Phase classification: P3b --> P3

|||||||||| Retrospective data, Review, Journal: Efficacy and safety of biologics for oral corticosteroid-dependent asthma: A systematic review and network meta-analysis. (Pubmed Central) - Nov 17, 2023
In OCS-dependent patients with asthma, benralizumab, dupilumab, and mepolizumab were superior to placebo in reducing the OCS dose. Evaluating baseline biomarkers helps in choosing the proper biologics to maximize treatment effects.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors. (Pubmed Central) - Nov 14, 2023
Our study confirmed the effectiveness and safety of tralokinumab. In particular, a higher pruritus, a relapsing course of the disease, a reduced EASI, a reduced IGA, and a brief duration of the disease seem to be associated with the fastest onset of treatment effectiveness.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Review, Journal: A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults. (Pubmed Central) - Nov 13, 2023
Tralokinumab has proven efficacious and well-tolerated in a large proportion of patients confirming its value for treating moderate-to-severe AD from age 12?years onwards; it quickly improves itching and can maintain a high-level of response over time; it can be administered with flexible dosing schedules. Future studies will further clarify the role of IL-13 pathway and which patients would be best suited to tralokinumab, shifting AD treatment into an era of precision medicine.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Observational data, Journal: Tralokinumab Improves Clinical Scores in Adolescents with Severe Atopic Dermatitis: A Real-life Multicentric Observational Study. (Pubmed Central) - Nov 4, 2023
Future studies will further clarify the role of IL-13 pathway and which patients would be best suited to tralokinumab, shifting AD treatment into an era of precision medicine. No abstract available

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Review, Journal: The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents. (Pubmed Central) - Oct 22, 2023
Based on the results of these trials and the preliminary results of trials conducted on adolescents with AD, tralokinumab effectively alleviates symptoms with tolerable adverse effects. Extending the use of tralokinumab to adolescents with moderate-to-severe AD seems promising for the future.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis. (Pubmed Central) - Oct 22, 2023
The small sample size limited generalizations from this analysis. The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD.

||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed, Monotherapy:  Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) (clinicaltrials.gov) -  Oct 19, 2023
P2, N=53, Active, not recruiting,  Sponsor: LEO Pharma
The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD. Recruiting --> Active, not recruiting

|||||||||| Retrospective data, Review, Journal, Immunomodulating: Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. (Pubmed Central) - Oct 13, 2023
Supporting results for continuous measures, upadacitinib 30 mg daily and abrocitinib 200 mg daily are the most efficacious with regards to binary efficacy endpoints up to 16 weeks in adults, followed by upadacitinib 15 mg daily, dupilumab and abrocitinib 100 mg daily. Dupilumab and both doses of upadacitinib and abrocitinib are more efficacious than baricitinib 4 and 2 mg daily and tralokinumab.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1. (Pubmed Central) - Oct 7, 2023
P3
NCT03160885 (ECZTRA 2); study start date: 12 June, 2017; primary completion date: 4 September, 2019; study completion date: 14 August, 2019. Video abstract: Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1 (MP4 362818 KB).

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control (e-Poster Hall) - Sep 27, 2023 - Abstract #EADV2023EADV_4679;
P3
Video abstract: Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1 (MP4 362818 KB). Continuous use of tralokinumab

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials (e-Poster Hall) - Sep 27, 2023 - Abstract #EADV2023EADV_4677;
P2, P3
Continuous use of tralokinumab Long-term use of tralokinumab, for up to 4.5 years, was well tolerated, and the pattern of AEs was consistent with the initial placebo-controlled treatment period and with no new safety signals identified.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Review, Journal: Clinical trials of antibody drugs in the treatments of atopic dermatitis. (Pubmed Central) - Sep 20, 2023
Notably, several antibody drugs have exhibited high efficacy in treating atopic dermatitis in previous studies, demonstrating that they could be therapeutic methods for AD patients. Herein, we reviewed the clinical trials of antibody drugs in the treatment of AD, which provides a useful guideline for clinicians to treat patients with AD in clinics.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis. (Pubmed Central) - Sep 18, 2023
This case suggests, that not only a dual IL-4-/IL-13-blockade, but also a selective IL-13-inhibition is able to skew immune responses toward IL-17 cytokine pathway-related disease. However, no clinical scores exist to predict the development of paradoxical psoriasis in patients with AD during therapy with biologics.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps. (Pubmed Central) - Sep 7, 2023
With the introduction of biologicals for AD from the age of six?months, potential challenges within the implementation of biologicals may arise. Therefore, we aim to discuss current practical challenges and knowledge gaps of the treatment with biologicals in infants and preschoolers with AD.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Retrospective data, Review, Journal, Adverse events: Incidence of conjunctivitis adverse event in patients treated with biologics for atopic dermatitis: A systematic review and meta-analysis. (Pubmed Central) - Sep 7, 2023
Therefore, we aim to discuss current practical challenges and knowledge gaps of the treatment with biologicals in infants and preschoolers with AD. No abstract available

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Review, Journal: Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents. (Pubmed Central) - Sep 1, 2023
The aim of this review is to update knowledge on the standard of care and recent advancements in the control of skin inflammation. In light of recent guidelines, we report on the clinical efficacy of novel treatments, with special attention to situations where biologics and small molecules are involved.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron, Mitchga (nemolizumab) / Roche, Maruho, Galderma
Journal: English version of Japanese guidance for biologics in treating atopic dermatitis. (Pubmed Central) - Aug 31, 2023
antibody, was approved for pruritus of AD, and tralokinumab, an anti-IL-13 antibody, was approved for AD...In treatment with biologics, it is important to consider disease factors (activity and severity), treatment factors (dosage and administration as well as the efficacy and safety), and patients' background characteristics (age and comorbidities) and share this information with patients when choosing treatment options. This guidance was developed for board-certified dermatologists who specialize in treating AD, and for promoting the proper use of biologics, taking into account the variety of factors in individual patients.

|||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Atopic dermatitis and ocular allergy: common mechanisms and uncommon questions. (Pubmed Central) - Aug 31, 2023
Modern cytokine-targeted therapies for AD showed elevated risk for developing conjunctivitis. Recently developed noninvasive sampling techniques should be leveraged to identify AD endotypes associated with AED and with dupilumab-associated ocular outcomes.



	Diseases Companies Products Productz Mechanisms of Action Sites